8 November 2020 – Walder Wyss has advised Swisscanto Invest in connection with its investment as lead investor in a CHF 14 mio. Series B Financing Round of Memo Therapeutics, an innovator in the field of antibody discovery and immune repertoire analysis. Proceeds from the financing round will be primarily used to advance development of MTX-COVAB, Memo Therapeutics’ lead antibody candidate for the treatment of COVID-19, through to Phase II clinical studies.

The Walder Wyss team has been led by Alex Nikitine (Partner, Corporate/M&A) and included Thiemo Sturny (Partner, Corporate/M&A), Dimitrios Berger (Associate, Corporate/M&A), Hugh Reeves (Senior Associate, IP/IT) and Judith Rothen (Trainee, Corporate/M&A).